Global Cord Blood Corp is a diagnostics & research business based in the US. Global Cord Blood shares (CO) are listed on the NYSE and all prices are listed in US Dollars. Global Cord Blood employs 1,215 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $3.00 |
|---|---|
| 52-week range | $2.10 - $5.50 |
| 50-day moving average | $2.91 |
| 200-day moving average | $3.88 |
| Wall St. target price | $15.00 |
| PE ratio | 4.6875 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.64 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3 from 2022-07-01
| 1 week (2022-06-28) | -5.66% |
|---|---|
| 1 month (2022-06-03) | -13.29% |
| 3 months (2022-04-05) | -23.47% |
| 6 months (2022-01-05) | -34.07% |
| 1 year (2021-07-02) | -44.34% |
|---|---|
| 2 years (2020-07-02) | 0.33% |
| 3 years (2019-07-05) | 5.72 |
| 5 years (2017-07-05) | 9.79 |
Valuing Global Cord Blood stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Global Cord Blood's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Global Cord Blood's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Global Cord Blood shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Global Cord Blood's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $663.8 million.
The EBITDA is a measure of a Global Cord Blood's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.2 billion |
|---|---|
| Operating margin TTM | 49.26% |
| Gross profit TTM | $980.7 million |
| Return on assets TTM | 4.77% |
| Return on equity TTM | 11.78% |
| Profit margin | 41.98% |
| Book value | $39.28 |
| Market capitalisation | $364.7 million |
TTM: trailing 12 months
We're not expecting Global Cord Blood to pay a dividend over the next 12 months.
Over the last 12 months, Global Cord Blood's shares have ranged in value from as little as $2.1 up to $5.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Global Cord Blood's is 0.4065. This would suggest that Global Cord Blood's shares are less volatile than average (for this exchange).
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2021, it operated three cord blood banks in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.